Lung Transplantation for Pleuroparenchymal Fibroelastosis

Lung Transplantation for Pleuroparenchymal Fibroelastosis : a French Multicentric Retrospective Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05044390

Enrollment

Registered

2021-09-14

Start date

2021-04-01

Completion date

2021-11-01

Last updated

2021-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibroelastosis

Brief summary

This retrospective observational study will evaluate the outcomes of lung transplantation for a rare cause of interstitial lung disease called pleuroparenchymal fibroelastosis. Data will be collected from all transplantation center in France.

Interventions

PROCEDURELung transplantation (single, lobar or bilateral lung transplantation)

Lung transplantation were performed for end-stage interstitial lung disease secondary to pleuroparenchymal fibroelastosis

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Lung transplantation (any type) for pleuroparenchymal fibroelastosis * Histologically confirmed pleuroparenchymal fibroelastosis on the recipient lungs

Exclusion criteria

* All other interstitial lung disease than pleuroparenchymal fibroelastosis * Pleuroparenchymal fibroelastosis who didn't underwent lung transplantation

Design outcomes

Primary

Measure	Time frame	Description
Post-operative mortality	Any death up to 90 days after lung transplantation	Any death after lung transplantation during the first 30 days or during the hospitalization following the lung transplantation (in-hospital mortality)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026